Shire Plc (SHPG)

179.20
7.05 4.10
Prev Close 172.15
Open 176.60
Day Low/High 175.71 / 181.22
52 Wk Low/High 123.73 / 182.47
Volume 5.32M
Avg Volume 1.63M
Exchange
Shares Outstanding 300.99M
Market Cap 54.82B
EPS 14.30
Div & Yield 1.06 (0.59%)
Second Quarter Predictions

Second Quarter Predictions

Better-than-expected earnings will help soothe market jitters in the second quarter.

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.

The Dow Falls Into Wednesday's Close

The Dow Falls Into Wednesday's Close

Strength in the morning yields to weakness in the afternoon session as stocks are sold off Wednesday.

Takeda Pharmaceutical Confirms Takeover Interest in U.K.-Listed Shire Plc

Takeda Pharmaceutical Confirms Takeover Interest in U.K.-Listed Shire Plc

Shire Pharmaceuticals shares hit a year-to-date high Wednesday after Japan's biggest drugmaker, Takeda, confirmed it may make a takeover approach for the U.K.-listed group.

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

The New #35 Most Shorted Nasdaq 100 Component: Shire

The New #35 Most Shorted Nasdaq 100 Component: Shire

The most recent short interest data has been released for the 12/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche sees success in trials for its cancer and hemophilia drugs

Weekly Roundup

The markets' climb hits a detour at the end of the week. In the portfolio, after adding five names to the bullpen, we promoted one of them to the portfolio.

Billionaire Hedge Fund Manager Leon Cooperman Gave His Top 5 Cheap Stocks

Billionaire Hedge Fund Manager Leon Cooperman Gave His Top 5 Cheap Stocks

Cooperman founded Omega Advisers in 1991.

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

A number of biotech-related stocks were down pre-market after announcing plans for public offerings.

Shire Gains as it Seeks European Approval For Dry Eye Treatment

Shire Gains as it Seeks European Approval For Dry Eye Treatment

The drug would be the first such treatment in Europe.

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead

Tesla and Apple Better Deliver Big-Time or Look Out Below -- Week Ahead

The labor market goes under inspection and Apple releases its earnings report.

Shire Stock Rising on Takeover Talks

Shire Stock Rising on Takeover Talks

Shire is also said to have hired its own defense advisers to ward off low bids.

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

Here are the activist investor's next potential targets.

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon

Jana Partners Liquidates Whole Foods Stake After Engineering Industry-Transforming Sale To Amazon

The activist will gain $320 million on the sale, which suggests that the fund either doesn't believe a higher bidder is coming or that they need the cash.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Biotech Movers: Shire, Bellicum, Organovo

Biotech Movers: Shire, Bellicum, Organovo

Shire, Bellicum Pharmaceuticals and Organovo Holdings were among the biotech stock movers in premarket trading on June 22.

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

The Activist Who Pushed Whole Foods Into the Arms of Amazon Could Target These Companies Next

Here are the activist investor's next potential targets.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

Shire Stock Rises Premarket on Positive Phase 3 Results for Angiodema Treatment

The study tested the drug on patients aged 12 years and older for 26 weeks.

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

European Stocks Mixed as Frankfurt Rises, Paris Falls

European Stocks Mixed as Frankfurt Rises, Paris Falls

The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.

Everything We Know About BioCryst's New HAE Drug

Everything We Know About BioCryst's New HAE Drug

BioCryst's Hereditary angioedema drug-trial results not compelling.

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Also up early Thursday: Bellicum and Novocure.